These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17595578)

  • 21. [Aliskiren hemifumarate].
    Kappert K; Unger T; Kintscher U
    Dtsch Med Wochenschr; 2008 Jun; 133(24):1308-12. PubMed ID: 18465684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S; Choy M
    Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W; Hermanowicz JM
    Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin inhibition in hypertension.
    Gradman AH; Kad R
    J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension.
    Riccioni G; Vitulano N; D'Orazio N; Bellocci F
    Adv Ther; 2009 Jul; 26(7):700-10. PubMed ID: 19649581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibition of the renin system by aliskiren and valsartan.
    Oparil S; Yarows SA; Patel S; Zhang J; Satlin A
    Lancet; 2007 Sep; 370(9593):1126-7. PubMed ID: 17905160
    [No Abstract]   [Full Text] [Related]  

  • 29. Aliskiren: a novel renin inhibitor for hypertension.
    Parmar DM; Jadav SP
    Indian J Physiol Pharmacol; 2007; 51(1):99-101. PubMed ID: 17877301
    [No Abstract]   [Full Text] [Related]  

  • 30. A new weapon against hypertension. Recently approved medication lowers blood pressure, reducing risks of heart failure, stroke, heart attack, aneurysm, and kidney failure.
    Heart Advis; 2007 Jun; 10(6):3. PubMed ID: 17654793
    [No Abstract]   [Full Text] [Related]  

  • 31. Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema.
    Anzaldua DA; Schmitz PG
    Am J Kidney Dis; 2008 Mar; 51(3):532-3. PubMed ID: 18295074
    [No Abstract]   [Full Text] [Related]  

  • 32. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042
    [No Abstract]   [Full Text] [Related]  

  • 33. Aliskiren for hypertension in adults.
    Drug Ther Bull; 2008 Oct; 46(10):73-6. PubMed ID: 18832257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aliskiren: the first renin inhibitor for clinical treatment.
    Jensen C; Herold P; Brunner HR
    Nat Rev Drug Discov; 2008 May; 7(5):399-410. PubMed ID: 18340340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin inhibitors: An important advance in hypertension treatment?
    Ferro A; Pitt B
    Int J Clin Pract; 2006 Nov; 60(11):1336-7. PubMed ID: 17073828
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):115-28. PubMed ID: 21105865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aliskiren: a new drug for an old problem.
    Barrios V; Escobar C
    Cardiovasc Hematol Agents Med Chem; 2010 Jan; 8(1):1-10. PubMed ID: 20210772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children.
    Flynn JT
    Pediatr Nephrol; 2011 Mar; 26(3):491-2. PubMed ID: 21161281
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension.
    Sullivan JE; Keefe D; Zhou Y; Satlin L; Fang H; Yan JH
    Clin Pediatr (Phila); 2013 Jul; 52(7):599-607. PubMed ID: 23610239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.